



Dynogen Pharmaceuticals Contacts

Robert Lorette, Chief Business Officer and SVP
Lee Brettman, President and CEO
Dynogen Pharmaceuticals, Inc.
(617) 357-8000

Feinstein Kean Healthcare Contacts

Shannon Altimari
Feinstein Kean Healthcare
(617) 577-8110

FOR IMMEDIATE RELEASE

DYNOGEN PHARMACEUTICALS, INC. ENTERS INTO OVERACTIVE BLADDER COLLABORATION WITH JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT

Boston, MA, January 5, 2004 – Dynogen Pharmaceuticals, Inc. today announced that it has entered into a collaboration with Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), a Division of Janssen Pharmaceutica, N.V. in Beerse, Belgium, under which Dynogen will utilize its *in vivo* pharmacology platform for genitourinary and gastrointestinal disorders to study several neurological compounds for the treatment of overactive bladder. The alliance is Dynogen’s first overactive bladder collaboration with a major pharmaceutical company. Financial terms were not disclosed.

Karl Thor, Ph.D., Dynogen’s Chief Scientific Officer, commented, “We welcome this collaboration with J&JPRD which utilizes Dynogen’s world leading neuropharmacology platform and neurobiology expertise. The Dynogen platform is built around a series of proprietary predictive, *in vivo* models for overactive bladder, and other genitourinary and gastrointestinal disorders. Our focused collaboration with J&JPRD will complement our existing internal research program from which we have validated a number of exciting new targets for the treatment of overactive bladder.”

Dynogen President and CEO, Lee Brettman, M.D., FACP added, “The agreement highlights the progress we have made in applying our proprietary neuropharmacology and drug development capabilities to discover and develop first-in-class and best-in-class therapies for genitourinary and gastrointestinal disorders.”

Overactive bladder is a symptom complex characterized by urinary urgency, frequency and nocturia. In extreme cases of this condition, episodes of incontinence can occur. Approximately 32 million people in the United States suffer from overactive bladder. The pharmacological treatments that are currently available target the smooth muscle of the bladder and often result in a compromise of normal micturition accompanied by frequent side effects such as dry mouth and drowsiness. In addition, the efficacy observed in the clinical setting with this class of drugs has not been impressive. Dynogen’s approach to treat overactive bladder is to address the neurological underpinnings of the disorder rather than the smooth muscle alone, resulting in an increase in the efficacy of the treatment and a reduction in the side effects. Since Dynogen’s initial financing 15 months ago, it has established a pipeline that includes two

clinical candidates scheduled to enter Phase II clinical trials in early 2004. The pipeline includes DDP-225 for the treatment of IBS, and DDP-200 in the area of overactive bladder.

About Dynogen Pharmaceuticals, Inc.

Dynogen Pharmaceuticals, Inc. is a neuroscience-based drug discovery and development company targeting first-in-class and best-in-class therapies for genitourinary and gastrointestinal disorders. The company reduces the time required and the risk involved in product development by using its predictive *in vitro* and *in vivo* pharmacology platform and experienced development team to identify and reposition neurological targets and compounds for genitourinary and gastrointestinal indications. Dynogen is applying these capabilities to rapidly build a pipeline of clinical and preclinical programs addressing major underserved markets such as overactive bladder, irritable bowel syndrome and sexual dysfunction. For additional information, please visit www.dynogen.com.

###